Navigation Links
Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
Date:10/14/2008

acturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, we may be unable to secure an appropriate business partner for our follow-on biologics business, our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to refle
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
2. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
3. Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
4. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
5. Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
6. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
7. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
8. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
9. Baxter Initiates Phase III Trial for the Treatment of Alzheimers Disease
10. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
11. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Sanofi (EURONEXT: SAN and NYSE: SNY ) announced ... , examining the selective JAK2 inhibitor SAR302503 for myelofibrosis ... The primary endpoint assessed the proportion of patients achieving ... in previous trials, the most common adverse events were ... presented at an upcoming medical congress. ...
(Date:5/17/2013)... Mass. , May 17, 2013  Boston Scientific ... participate at the annual EuroPCR Scientific Program May 21-24 ... are pleased to present a particularly rich and diversified ... Keith Dawkins , M.D., global chief medical ... trials will be presented, including the NG PROMUS trial, ...
(Date:5/16/2013)... 16, 2013  PTC Therapeutics, Inc., today announced that ... with the U.S. Securities and Exchange Commission ("SEC") relating ... stock. The number of shares to be offered and ... determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) ... joint book-running managers for the offering. Cowen and Company ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
... Conn. , May 14 Zargis Medical Corp., ... today announced that its Zargis Cardioscan device and the compatible ... of a Gold Award on April 29th at ... Channel in New York City . The prestigious Gold ...
... , Germany , May 14, 2010 On ... international user meeting of endoscopic,spinal surgery in Veenhuizen/Niederlande. Besides the ten ... Europe , the United States ,and other countries are expected ... will be opened with a keynote lecture of,Prof. Dr. Gerbrand ...
Cached Medicine Technology:Zargis Medical Strikes Gold at 2010 Edison Awards 2joimax(R) Holds the First International TESSYS(R) User Meeting in Veenhuizen, The Netherlands, and Announces the Launch of Various New Products for Endoscopic Spinal Surgery 2
(Date:5/18/2013)... Angeles, California (PRWEB) May 18, 2013 Online ... to be Rolex watch owners at a fraction ... collection of luxury timepieces in the world, buyers are urged ... As compared to buying a Rolex watch from a brick-and-mortar ... pre owned Rolex watches priced at unbelievable rates. Although ...
(Date:5/18/2013)... Dennis Thompson HealthDay Reporter , , FRIDAY, May ... unveils the latest edition of what is considered the ... its many changes continues. "This is unprecedented, the ... Jeffrey Lieberman, president-elect of the American Psychiatric Association (APA). ... what it is. You have to evaluate it and ...
(Date:5/18/2013)... a few extra cups of coffee each month might ... known as primary sclerosing cholangitis (PSC), a new study ... Minn., found that drinking coffee was associated with a ... to cirrhosis of the liver, liver failure and biliary ... relationship. "While rare, PSC has extremely detrimental ...
(Date:5/18/2013)... 2013) The use of a smartphone application ... to new research presented today at Digestive Disease ... in advance of the procedure, includes dietary restrictions ... taken at strict intervals. The better the preparation, ... cancer and precancerous polyps in the colon. The ...
(Date:5/18/2013)... -- Regular consumption of coffee is associated with ... an autoimmune liver disease, Mayo Clinic research shows. ... Disease Week 2013 conference in Orlando, Fla. ... bile ducts that results in inflammation and subsequent ... liver, liver failure and biliary cancer. , "While ...
Breaking Medicine News(10 mins):Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New smartphone application improves colonoscopy preparation 2
... confirms that hormone replacement therapy (HRT) should not be prescribed ... help prevent chronic conditions such as heart disease . ... safe short term treatment for younger women in early menopause ... ,In 2002, the Womens Health Initiative (WHI) trial found that ...
... have, the slower you age . ,Researchers at ... moles in a study of 1,800 twins, at the Twin Research Unit ... the more likely their DNA was to have the properties to fight ... in spite of the fact that moles are linked with ...
... 13 million kilograms of antibiotics are used to raise ... are used for growth advancement and disease prevention ... up as manure, which is commonly applied to agricultural ... on manure-altered soils are exposed to antibiotics. , ...
... Thiruvananthapuram Zoo has barred the entry of visitors for a week ... reportedly lost its entire stock of Indian gaur (Bos Gaurus) -- ... the week gone by. ,It was confirmed last ... the death of animals. ,The zoo was being ...
... to a particular variety of sugar present on the surface ... are regarded as mindless killers. White blood cells (WBC) form ... our internal body. They protect our body from various kinds ... wiping out any intruder that invades the body. A new ...
... she feared that her recent miscarriage was god's way of punishing ... lost her baby when she was three months pregnant, said that ... of this year, she thought she would never recover after losing ... is all this happening?' I thought it was God's punishment for ...
Cached Medicine News:Health News:Study Confirms No HRT Benefit for Older Women 2Health News:Study Confirms No HRT Benefit for Older Women 3Health News:Dotted All Over? - Count Yourself Lucky 2Health News:Contamination of the Environment by Antibiotics Fed to Livestock 2Health News:WBC Selective About Sugar 2
... fully threaded 2.4 mm diameter titanium suture anchor. ... using either a powered handpiece or manually with ... implant is ideal for Bankart and SLAP repairs ... very high pull-out strengths. FASTak anchors are available ...
... The Bio-Corkscrew FT (fully threaded) is a ... to be inserted flush with the cortical ... anchor stability. The fully threaded design substantially ... with protruding eyelets. The fully threaded design ...
... is a 3 mm x 14 mm bioabsorbable ... the shoulder, knee, elbow and ankle. The exclusive ... body of the anchor and provides superior resistance ... This unique eyelet design allows the attached suture ...
... Suture Kit is available for ... procedures. This kit contains a ... three different colored versions of ... differentiation, large cutting Spring Eye ...
Medicine Products: